CS
TNGX icon

Credit Suisse’s Tango Therapeutics TNGX Stock Holding History

Credit Suisse’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$519K Buy
65,357
+3,595
+6% +$38.5K ﹤0.01% 2626
2023
Q4 		$611K Sell
61,762
-981
-2% -$8.52K ﹤0.01% 2627
2023
Q3 		$706K Buy
62,743
+10,176
+19% +$62.1K ﹤0.01% 2494
2023
Q2 		$175K Sell
52,567
-1,277
-2% -$4.59K ﹤0.01% 3108
2023
Q1 		$213K Buy
53,844
+2,472
+5% +$14.3K ﹤0.01% 3097
2022
Q4 		$372K Buy
51,372
+23,593
+85% +$166K ﹤0.01% 2934
2022
Q3 		$100K Buy
27,779
+234
+0.8% +$999 ﹤0.01% 3429
2022
Q2 		$125K Buy
27,545
+2,361
+9% +$14.3K ﹤0.01% 3483
2022
Q1 		$191K Buy
25,184
+1,762
+8% +$15.3K ﹤0.01% 3385
2021
Q4 		$256K Buy
+23,422
New +$282K ﹤0.01% 4183

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Credit Suisse's TNGX Position: Q1 2024 in Review

Credit Suisse increased its Tango Therapeutics (TNGX) stake by 5.8% in Q1 2024, buying an estimated $38.5K and bringing the position to 65,357 shares worth $519K. The position accounts for ﹤0.01% of the portfolio, ranked #2626.

Credit Suisse first reported a position in TNGX in Q4 2021 and has held it in 10 quarters since. The position peaked at $706K in Q3 2023. 126 funds tracked by Wall St. Rank hold TNGX as of Q1 2024.

  • Credit Suisse held 65,357 shares of Tango Therapeutics worth $519K as of Q1 2024.
  • Credit Suisse bought 3,595 Tango Therapeutics shares in Q1 2024, an estimated $38.5K.
  • Tango Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2626 holding.
  • Credit Suisse first reported a position in Tango Therapeutics in Q4 2021 and has held it in 10 quarters since.
  • Credit Suisse's Tango Therapeutics position peaked at $706K in Q3 2023.
  • 126 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.